Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Contact us for Wholesale Orders
Originally developed and FDA-approved under the brand name Egrifta, Tesamorelin was intended to reduce visceral fat accumulation in HIV-positive patients with lipodystrophy
Additionally, the appetite-suppressing effects of GLP-1 medications can partially attenuate over time as receptors adjust to sustained stimulation
More Related Reports Preventive Asthma Drugs Market Implantable Drug Device Market Drug Blister Packaging Market Alzheimers Drug Market Over the Counter Drugs Market Glp 1 Analogues Market Company Profile Glp 1 Analogues Market Highlights FAQs Glp-1 Analogues Market Size was valued at USD 45.3 Billion in 2024 and is expected to reach USD 606.3 Billion by 2034, growing at a CAGR of 33% Glp-1 Analogues Market is segmented into Product, Drug Class, Route of Administration, Distribution Channel, and Region
US$ 21.06
US$ 22.89
US$ 23.98
US$ 27.56
US$ 22.22
